Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Vuocolo

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Vaccine|July 9, 2013
Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in malesStephen E Goldstone, Heiko Jessen, Joel M Palefsky, et al.
Lancet (London, England)|June 5, 2009
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trialNubia Muñoz, Ricardo Manalastas, Punee Pitisuttithum, et al.
Human Vaccines|June 30, 2011
Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adultsEdson D Moreira, Joel M Palefsky, Anna R Giuliano, et al.
The New England Journal of Medicine|October 28, 2011
HPV vaccine against anal HPV infection and anal intraepithelial neoplasiaJoel M Palefsky, Anna R Giuliano, Stephen Goldstone, et al.
Clinical and Vaccine Immunology : CVI|December 14, 2011
Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years oldRichard J Hillman, Anna R Giuliano, Joel M Palefsky, et al.
The Lancet. Oncology|September 24, 2013
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind studyMeletios Dimopoulos, David S Siegel, Sagar Lonial, et al.
Virology|July 24, 2013
Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studiesRichard J O Barnard, John A Howe, Robert A Ogert, et al.
The Journal of Infectious Diseases|December 15, 2010
External genital human papillomavirus prevalence and associated factors among heterosexual men on 5 continentsEftyhia Vardas, Anna R Giuliano, Stephen Goldstone, et al.
The Journal of Infectious Diseases|December 15, 2010
Prevalence of and risk factors for human papillomavirus (HPV) infection among HIV-seronegative men who have sex with menStephen Goldstone, Joel M Palefsky, Anna R Giuliano, et al.
The New England Journal of Medicine|February 4, 2011
Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in malesAnna R Giuliano, Joel M Palefsky, Stephen Goldstone, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Vaccine|July 9, 2013
Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in malesStephen E Goldstone, Heiko Jessen, Joel M Palefsky, et al.
Lancet (London, England)|June 5, 2009
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trialNubia Muñoz, Ricardo Manalastas, Punee Pitisuttithum, et al.
Human Vaccines|June 30, 2011
Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adultsEdson D Moreira, Joel M Palefsky, Anna R Giuliano, et al.
The New England Journal of Medicine|October 28, 2011
HPV vaccine against anal HPV infection and anal intraepithelial neoplasiaJoel M Palefsky, Anna R Giuliano, Stephen Goldstone, et al.
Clinical and Vaccine Immunology : CVI|December 14, 2011
Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years oldRichard J Hillman, Anna R Giuliano, Joel M Palefsky, et al.
The Lancet. Oncology|September 24, 2013
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind studyMeletios Dimopoulos, David S Siegel, Sagar Lonial, et al.
Virology|July 24, 2013
Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studiesRichard J O Barnard, John A Howe, Robert A Ogert, et al.
The Journal of Infectious Diseases|December 15, 2010
External genital human papillomavirus prevalence and associated factors among heterosexual men on 5 continentsEftyhia Vardas, Anna R Giuliano, Stephen Goldstone, et al.
The Journal of Infectious Diseases|December 15, 2010
Prevalence of and risk factors for human papillomavirus (HPV) infection among HIV-seronegative men who have sex with menStephen Goldstone, Joel M Palefsky, Anna R Giuliano, et al.
The New England Journal of Medicine|February 4, 2011
Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in malesAnna R Giuliano, Joel M Palefsky, Stephen Goldstone, et al.
Pageof 4